Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Spyre Therapeutics, Inc. (SYRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Spyre is a clinical-stage biotechnology company listed on the Nasdaq Global Select Market, and its filings document material events, financing activities, and key clinical development updates related to its long-acting antibody programs for inflammatory bowel disease and rheumatic diseases.
Recent Form 8-K reports describe, for example, interim Phase 1 results for SPY003, an investigational extended half-life antibody targeting the p19 subunit of IL-23, including safety and pharmacokinetic findings that the company states support potential quarterly or twice-yearly maintenance dosing. Other 8-K filings detail the initiation and structure of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, as well as financial results and preliminary cash balances for specific quarters.
Spyre’s filings also include disclosures about public equity offerings under its shelf registration statement on Form S-3. An 8-K dated October 15, 2025, for example, outlines the terms of an underwritten public offering of common stock, gross proceeds, and the company’s stated intention to use net proceeds to advance programs in IBD and rheumatic diseases, support preclinical and clinical work, manufacturing, and Phase 3 readiness activities, and provide working capital.
On Stock Titan, users can review these filings in sequence and use AI-powered tools to summarize lengthy documents, highlight key sections, and quickly identify items related to clinical data, financing, and other material events disclosed by Spyre Therapeutics.
Spyre Therapeutics, Inc. is holding its 2026 virtual annual stockholder meeting on May 27, 2026 to vote on four key items. Stockholders will elect three Class I directors, cast an advisory “say-on-pay” vote on executive compensation, ratify KPMG LLP as auditor, and approve an amended and restated 2016 Employee Stock Purchase Plan reserving 1,056,096 shares. The company highlights its classified board, supermajority voting and other governance practices, and notes 78,784,358 common shares outstanding as of April 2, 2026.
Spyre Therapeutics, Inc. Chief Executive Officer Turtle Cameron reported open-market sales of company stock. On April 1, 2026, he sold a total of 15,000 shares of common stock in two transactions, at weighted average prices of $49.20 and $49.92 per share.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Cameron directly holds 627,540 shares of Spyre Therapeutics common stock, including 116,168 shares that vest in monthly installments through November 2026, contingent on his continued service.
Spyre Therapeutics, Inc. Chief Medical Officer Sloan Sheldon exercised stock options and sold the resulting shares. On this Form 4, Sheldon exercised options to acquire 7,958 shares of common stock at an exercise price of $21.66 per share and immediately sold all 7,958 shares at $50.00 per share.
The filing notes that this transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025, indicating the timing was set in advance rather than being a discretionary market-timing decision.
Spyre Therapeutics Chief Financial Officer Scott L. Burrows reported an option exercise and related stock sales. On April 1, 2026, he exercised stock options to acquire 7,500 shares of common stock at an exercise price of $14.50 per share, fully using the remaining options covered in this filing.
On the same date, he sold 6,200 shares at a weighted average price of $49.21 and 1,300 shares at a weighted average price of $49.98 in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 97,994 shares of common stock, including 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.
The Vanguard Group filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Spyre Therapeutics Inc Common Stock. The amendment explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report holdings separately; the filing states the reported holdings include securities in the form of rights.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows reported option exercises and related share sales. He exercised a stock option for 2,500 shares of common stock at $14.50 per share through a derivative conversion. On the same date, he sold a total of 2,500 shares of common stock in open-market transactions at weighted average prices of $40.56 and $41.66 per share under a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly held 97,994 shares of common stock, which the filing notes include 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. The stock option originally covered 404,857 shares, with vesting over several years.
Spyre Therapeutics, Inc.'s Chief Executive Officer, Cameron Turtle, reported selling a total of 15,000 shares of common stock in open-market transactions on March 2, 2026. The sales, executed under a Rule 10b5-1 trading plan adopted on June 20, 2025, were completed in two trades at weighted average prices of $41.73 and $42.49, each reflecting multiple executions within stated price ranges. Following these transactions, the CEO directly holds 642,540 shares of common stock, which includes 130,683 shares scheduled to vest in monthly installments through November 2026, subject to continued service.